Study of Lymphoma in Asia
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01584141|
Recruitment Status : Completed
First Posted : April 24, 2012
Last Update Posted : November 27, 2020
- Study Details
- Tabular View
- No Results Posted
- How to Read a Study Record
- Lymphoma rates in Asia have been lower than in the West, but rates have been rising in recent years. Most studies of lymphoma patients have been conducted in the West. Less information is available about the factors that might contribute to the rise of lymphoma in Asia. Researchers want to collect medical and personal histories and samples from people who have recently been diagnosed with lymphoma. This information will help them study possible reasons for this increase.
- To collect samples and histories as part of an introductory study of lymphoma in Asia.
- People between 18 and 79 years of age who have entered study hospitals in Hong Kong, Taiwan, and mainland China for treatment for any type of lymphoma.
- Healthy volunteers between 18 and 79 who have never had lymphoma.
- Participants will be screened with a physical exam and medical history.
- They will provide blood samples and cheek cell samples for testing.
- Participants will complete a questionnaire about their personal health history. They will answer questions about exposures to chemicals like pesticides. They will also be asked about family medical history and work and residential history. Finally they will answer questions about lifestyle factors like diet and exercise.
- They will give permission for the researchers to see their medical records. Researchers will also have access to any tumor samples collected as part of treatment.
|Condition or disease|
|Lymphoma, Follicular Lymphoma, Non-Hodgkin Multiple Myleoma Lympocytic, Follicular Leukemia Hodgkin Lymphoma|
|Study Type :||Observational|
|Actual Enrollment :||13433 participants|
|Official Title:||A Multi-Center International Hospital-Based Case-Control Study of Lymphoma in Asia (AsiaLymph)|
|Actual Study Start Date :||July 5, 2011|
|Actual Primary Completion Date :||July 10, 2018|
|Actual Study Completion Date :||July 10, 2018|
Asian cases with lymphoid or myeloid neoplasma
Controls with selected non-cancer diagnosis who were hospitalized in Hong Kong, Chengdu and Tianjin of Mainland China, and Taiwan
- Evaluation of chemical exposures and genetic susceptibility [ Time Frame: 2020 ]A large-scale evaluation of genes associated with lymphoma in Asian populations that parallels efforts being conducted in Caucasian populations (e.g., currently a genome-wide association study (GWAS)) would be particularly informative because of Asian population genetic differences in patterns of LD and local haplotype structure.
- Explore relationship between other factors (viral infections, UV exposure, medical conditions, and lifestyle factors and non-Hodgkin Lymphoma [ Time Frame: 2020 ]Other factors potentially related to NHL, such as viral infections, UV exposure, medical conditions, and other lifestyle factors will also beexplored.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
|Ages Eligible for Study:||18 Years to 79 Years (Adult, Older Adult)|
|Sexes Eligible for Study:||All|
|Accepts Healthy Volunteers:||No|
|Sampling Method:||Probability Sample|
- INCLUSION CRITERIA:
Eligible cases will be patients at a participating hospital who are between 18 and 79 years of age at time of initial diagnosis and admitted or treated with incident diagnoses of any lymphoid or myeloid neoplasm including all NHL and Hodgkin disease. Although it is important to understand the etiology of lymphoma in children as well, this undertaking would require additional hospitals, instruments, expertise, and funding that are not currently available to our research team. Adults over the age of 80 are generally among the sickest patients in the hospital and often have multiple comorbidities, which may preclude their participation in an interview of this length. Cases will be permanent residents of the general geographic region that is served by the hospital at the time of diagnosis. Cases will include chronic lymphocytic leukemia/small lymphocytic lymphoma, Waldenstrom macroglobulinemia, plasmacytoma, multiple myeloma, aggressive NK cell leukemia, cutaneous lymphomas, myeloid neoplasms, and immunosuppression-associated cases (such as HIV, post transplant, Methotrexate use).
2,400 lymphoid neoplasm cases will be enrolled with less common subtypes in Asian populations including Hodgkin disease, multiple myeloma, chronic lymphocytic leukemia, and NK/T, T, follicular and marginal zone lymphoma, in order to increase statistical power to study risk factors for these tumors.
Cases with previous diagnosis of lymphoma, such as acute lymphoblastic lymphoma, multiple myeloma, chronic lymphocytic leukemia, and non-Hodgkin lymphoma, are ineligible.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01584141
|Tianjin Medical University Cancer Institute & Hospital|
|Hexi District, China, 300060|
|West China Hospital of Sichuan University|
|Sichuan, China, 610041|
|Queen Mary Hospital|
|Sai Ying Poon, Hong Kong|
|Buddhis Dalin Tzu Chi General Hospital|
|Dalin Town, Taiwan|
|Principal Investigator:||Qing Lan, M.D.||National Cancer Institute (NCI)|
|Responsible Party:||National Cancer Institute (NCI)|
|Other Study ID Numbers:||
|First Posted:||April 24, 2012 Key Record Dates|
|Last Update Posted:||November 27, 2020|
|Last Verified:||November 2020|
|Studies a U.S. FDA-regulated Drug Product:||No|
|Studies a U.S. FDA-regulated Device Product:||No|
Neoplasms by Histologic Type
Immune System Diseases